Table 2.
Adjusted RRs of reaching primary and secondary outcomes stratified by LEF/CYC treatment after 9 months in patients with TA.
| Before matching |
After matching |
|||||
|---|---|---|---|---|---|---|
| LEF group (n = 52) |
CYC group (n = 78) |
P | LEF group (n = 23) |
CYC group (n = 54) |
P | |
| CR % (95% CI) |
84.6 (74.5–94.8) |
59.0 (47.8–70.1) |
0.002* | 95.7 (86.6–100.0) |
63.0 (49.7–76.3) |
0.003* |
| RR (95% CI) |
1 | 0.3 (0.1–0.6) |
1 | 0.1 (0.0–0.6) |
||
| PR % (95% CI) |
9.6 (1.3–17.9) |
15.4 (7.2–23.6) |
0.339 | 4.3 (0–13.4) |
20.4 (9.3–31.5) |
0.095 |
| RR (95% CI) |
1 | 1.7 (0.6–5.2) |
1 | 5.6 (0.7–46.4) |
||
| ER % (95% CI) |
94.2 (87.7–100.0) |
74.4 (64.5–84.3) |
0.004* | 100 (100–100) |
83.3 (73.1–93.6) |
0.037* |
| RR (95% CI) |
1 | 0.2 (0.1–0.6) |
1 | 0.8 (0.3–2.1) |
||
RR, relative risk; TA, Takayasu’s arteritis; LEF, leflunomide; CYC, cyclophosphamide; CI, confidence interval; CR, complete remission; PR, partial remission; ER, effectiveness rate.
*
p < 0.05 was considered a significant different between the LEF and CYC groups.